A recent meeting of the FDA's Patient Engagement Advisory Committee convened by the agency's Center for Devices and Radiological Health covered the potential use of social media and other patient-generated data as a source of post-market medical device data. Panelists and speakers noted use of such information has benefits, such as reduced expense, easier patient follow-up and quicker FDA reaction to adverse events, but it brings several challenges, including privacy, accuracy and generalizability.
FDA's patient engagement panel discusses use of patient-generated data
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.